Showing posts from June, 2024

The FTC's new set of letters challenging patents listed in the Orange Book

 The FTC has sent out a new set of letters (dated April 30, 2024) to pharmaceutical companies in which the agency is challenging the eligibility of certain patents for listing in the FDA’s Orange Book. If you are interested in an easy way of reviewing these newly challenged patents (of which there are 125), I have created Orange Book Companion-style pages to do just that. In those custom pages each patent number is a link to the text of the challenged patent at the USPTO. Just go to the public Orange Book Companion home page ( ) and look for the section entitled “Patents disputed by the Federal Trade Commission.” There are two links in that section. One link will take you to the products that had one or more patents that were the subject of the FTC’s letters dated November 7, 2023. The other link will take you to the products that have one or more listed patents that are the subject of the FTC’s most recent letters. Clicking on the name of the product will t